Business 154 COVID studies have been retracted and it probably won’t matter Published 3 years ago on 3 September 2021 By Terry Power Share Tweet There have been 154 COVID-related studies retracted to date, according to Retraction Watch, including now-discredited papers on 5G and the coronavirus and ones recommending unproven drugs like ivermectin to treat COVID-19. Read More Related Topics:5g coronavirus5g covidcoronavirusCOVIDcovid paper retractioncovid study retractioncovid vaccinesCOVID-19FDAfda resignationsfda resignations covidfda resignations covid vaccinesivermectinivermectin covidmatterretractedretracted covid papersretracted covid studiessb8studiesTexas abortion lawtexas sb8theranos trialwont Up Next Investors press pause on the stocks and crypto rally ahead of today’s mammoth jobs report Don't Miss Delivery apps shouldn’t take orders during natural disasters Continue Reading You may like Why watermarking AI-generated content won’t guarantee trust online Decoding the data of the Chinese mpox outbreak China is suddenly dealing with another public health crisis: mpox Covid hasn’t entirely gone away—here’s where we stand Lab-grown meat just reached a major milestone. Here’s what comes next. Making data matter in real time Business These fast-growing Sun Belt cities suffer from high inflation Published 3 years ago on 4 May 2022 By Terry Power U.S. migration hotspots tend to have the highest inflation | Fortune You need to enable JavaScript to view this site. Continue Reading Business The U.S. is seizing a $325 million helipad-equipped megayacht in Fiji. The question is which Russian oligarch it belongs to Published 3 years ago on 4 May 2022 By Terry Power Oligarch sanctions: U.S. seizing $325 million megayacht in Fiji. The question is which Russian billionaire it belongs to | Fortune You need to enable JavaScript to view this site. Continue Reading Business Investors bank on today’s ‘once-in-a-generation’ Fed hike to be one of several Published 3 years ago on 4 May 2022 By Terry Power Fed rate hike: decision day rattles markets as investors worry that a giant ‘once-in-a-generation’ hike will be one of several this year | Fortune You need to enable JavaScript to view this site. Continue Reading